Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Pyrrolo[2,3-d]pyrimidine (7-deazapurine) as a privileged scaffold in design of antitumor and antiviral nucleosides

P. Perlíková, M. Hocek,

. 2017 ; 37 (6) : 1429-1460. [pub] 20170823

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, přehledy, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc18024716

7-Deazapurine (pyrrolo[2,3-d]pyrimidine) nucleosides are important analogues of biogenic purine nucleosides with diverse biological activities. Replacement of the N7 atom with a carbon atom makes the five-membered ring more electron rich and brings a possibility of attaching additional substituents at the C7 position. This often leads to derivatives with increased base-pairing in DNA or RNA or better binding to enzymes. Several types of 7-deazapurine nucleosides with potent cytostatic or cytotoxic effects have been identified. The most promising are 7-hetaryl-7-deazaadenosines, which are activated in cancer cells by phosphorylation and get incorporated both to RNA (causing inhibition of proteosynthesis) and to DNA (causing DNA damage). Mechanism of action of other types of cytostatic nucleosides, 6-hetaryl-7-deazapurine and thieno-fused deazapurine ribonucleosides, is not yet known. Many 7-deazaadenosine derivatives are potent inhibitors of adenosine kinases. Many types of sugar-modified derivatives of 7-deazapurine nucleosides are also strong antivirals. Most important are 2'-C-methylribo- or 2'-C-methyl-2'-fluororibonucleosides with anti-HCV activities (several compounds underwent clinical trials). Some underexplored areas of potential interest are also outlined.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18024716
003      
CZ-PrNML
005      
20180716122725.0
007      
ta
008      
180709s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/med.21465 $2 doi
035    __
$a (PubMed)28834581
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Perlíková, Pavla $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, CZ-16610, Prague 6, Czech Republic.
245    10
$a Pyrrolo[2,3-d]pyrimidine (7-deazapurine) as a privileged scaffold in design of antitumor and antiviral nucleosides / $c P. Perlíková, M. Hocek,
520    9_
$a 7-Deazapurine (pyrrolo[2,3-d]pyrimidine) nucleosides are important analogues of biogenic purine nucleosides with diverse biological activities. Replacement of the N7 atom with a carbon atom makes the five-membered ring more electron rich and brings a possibility of attaching additional substituents at the C7 position. This often leads to derivatives with increased base-pairing in DNA or RNA or better binding to enzymes. Several types of 7-deazapurine nucleosides with potent cytostatic or cytotoxic effects have been identified. The most promising are 7-hetaryl-7-deazaadenosines, which are activated in cancer cells by phosphorylation and get incorporated both to RNA (causing inhibition of proteosynthesis) and to DNA (causing DNA damage). Mechanism of action of other types of cytostatic nucleosides, 6-hetaryl-7-deazapurine and thieno-fused deazapurine ribonucleosides, is not yet known. Many 7-deazaadenosine derivatives are potent inhibitors of adenosine kinases. Many types of sugar-modified derivatives of 7-deazapurine nucleosides are also strong antivirals. Most important are 2'-C-methylribo- or 2'-C-methyl-2'-fluororibonucleosides with anti-HCV activities (several compounds underwent clinical trials). Some underexplored areas of potential interest are also outlined.
650    _2
$a buňky A549 $7 D000072283
650    _2
$a zvířata $7 D000818
650    _2
$a protinádorové látky $x chemická syntéza $x chemie $x farmakologie $7 D000970
650    _2
$a antivirové látky $x chemická syntéza $x chemie $x farmakologie $7 D000998
650    _2
$a racionální návrh léčiv $7 D015195
650    _2
$a screeningové testy protinádorových léčiv $7 D004354
650    _2
$a HeLa buňky $7 D006367
650    _2
$a buňky Hep G2 $7 D056945
650    _2
$a lidé $7 D006801
650    _2
$a nukleosidy $x chemická syntéza $x chemie $x farmakologie $7 D009705
650    _2
$a puriny $x chemie $7 D011687
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Hocek, Michal $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, CZ-16610, Prague 6, Czech Republic. Department of Organic Chemistry, Faculty of Science, Charles University in Prague, CZ-12843, Prague 2, Czech Republic.
773    0_
$w MED00003265 $t Medicinal research reviews $x 1098-1128 $g Roč. 37, č. 6 (2017), s. 1429-1460
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28834581 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180709 $b ABA008
991    __
$a 20180716123023 $b ABA008
999    __
$a ok $b bmc $g 1316847 $s 1021637
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 37 $c 6 $d 1429-1460 $e 20170823 $i 1098-1128 $m Medicinal research reviews $n Med Res Rev $x MED00003265
LZP    __
$a Pubmed-20180709

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...